JP2007509947A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509947A5 JP2007509947A5 JP2006538172A JP2006538172A JP2007509947A5 JP 2007509947 A5 JP2007509947 A5 JP 2007509947A5 JP 2006538172 A JP2006538172 A JP 2006538172A JP 2006538172 A JP2006538172 A JP 2006538172A JP 2007509947 A5 JP2007509947 A5 JP 2007509947A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- disease
- therapeutic agent
- compound
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 18
- 229940124597 therapeutic agent Drugs 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- 125000003107 substituted aryl group Chemical group 0.000 claims 10
- 125000000547 substituted alkyl group Chemical group 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 208000019693 Lung disease Diseases 0.000 claims 7
- 125000005842 heteroatom Chemical group 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 208000025966 Neurological disease Diseases 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical group C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 claims 1
- 102000009346 Adenosine receptors Human genes 0.000 claims 1
- 108050000203 Adenosine receptors Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51601903P | 2003-10-31 | 2003-10-31 | |
| US60/516,019 | 2003-10-31 | ||
| PCT/US2004/035453 WO2005042534A2 (en) | 2003-10-31 | 2004-10-26 | A2b adenosine receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007509947A JP2007509947A (ja) | 2007-04-19 |
| JP2007509947A5 true JP2007509947A5 (https=) | 2007-11-15 |
| JP4863876B2 JP4863876B2 (ja) | 2012-01-25 |
Family
ID=34549473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006538172A Expired - Lifetime JP4863876B2 (ja) | 2003-10-31 | 2004-10-26 | Ａ２ｂアデノシン受容体アンタゴニスト |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7449473B2 (https=) |
| EP (1) | EP1678181B1 (https=) |
| JP (1) | JP4863876B2 (https=) |
| KR (1) | KR20060111467A (https=) |
| CN (1) | CN1890241A (https=) |
| AT (1) | ATE419252T1 (https=) |
| AU (1) | AU2004285013A1 (https=) |
| BR (1) | BRPI0415888A (https=) |
| CA (1) | CA2544193C (https=) |
| DE (1) | DE602004018808D1 (https=) |
| ES (1) | ES2318363T3 (https=) |
| MX (1) | MXPA06004789A (https=) |
| WO (1) | WO2005042534A2 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039385A1 (es) | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
| US20060058322A1 (en) * | 2004-09-01 | 2006-03-16 | Dewan Zeng | Method of wound healing using A2B adenosine receptor antagonists |
| EP1799221A1 (en) | 2004-10-15 | 2007-06-27 | Cv Therapeutics, Inc. | Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists |
| MY140748A (en) * | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| NZ564326A (en) * | 2005-06-16 | 2010-01-29 | Cv Therapeutics Inc | Prodrugs of A2B adenosine receptor antagonists |
| ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| CA2644996A1 (en) * | 2006-03-02 | 2007-09-13 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
| TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
| CN101460501A (zh) * | 2006-06-05 | 2009-06-17 | 阿斯利康(瑞典)有限公司 | 作为髓过氧化物酶抑制剂的吡咯并[3，2-d]嘧啶-4-酮衍生物 |
| US7470697B2 (en) * | 2006-09-01 | 2008-12-30 | Adenosine Therapeutics, Llc | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors |
| GB0718434D0 (en) * | 2007-09-21 | 2007-10-31 | Vernalis R&D Ltd | New chemical compounds |
| GB0718432D0 (en) * | 2007-09-21 | 2007-10-31 | Vernalis R&D Ltd | New chemical compounds |
| TW200938200A (en) * | 2007-12-28 | 2009-09-16 | Dainippon Sumitomo Pharma Co | Methyl-substituted piperidine derivative |
| JP5460690B2 (ja) | 2008-03-26 | 2014-04-02 | アドヴィナス・セラピューティックス・リミテッド | アデノシンレセプターアンタゴニストとしてのヘテロ環化合物 |
| US20110118276A1 (en) * | 2008-07-16 | 2011-05-19 | Edward Leung | Methods of treating atherosclerosis |
| DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
| AU2010222289B2 (en) | 2009-03-13 | 2013-07-11 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds |
| EP2499142B1 (en) | 2009-11-09 | 2016-09-21 | Advinus Therapeutics Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
| EP2571882A1 (en) * | 2010-05-21 | 2013-03-27 | Gilead Sciences, Inc. | Heterocyclic flaviviridae virus inhibitors |
| CN103261200B (zh) | 2010-09-13 | 2016-03-30 | 阿迪维纳斯疗法有限公司 | 作为a2b腺苷受体拮抗剂的前药的嘌呤化合物、它们的制备方法及医药用途 |
| CA2862263C (en) | 2011-12-27 | 2016-09-06 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| WO2015003881A1 (en) * | 2013-07-08 | 2015-01-15 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
| JP6667092B2 (ja) * | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ | ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体 |
| MX2021008094A (es) | 2019-01-11 | 2021-09-21 | Omeros Corp | Metodos y composiciones para el tratamiento del cancer. |
| LT4122926T (lt) * | 2021-04-14 | 2025-07-25 | Shionogi & Co., Ltd. | Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1254915B (it) * | 1992-04-24 | 1995-10-11 | Gloria Cristalli | Derivati di adenosina ad attivita' a2 agonista |
| DE19535504A1 (de) | 1995-09-25 | 1997-03-27 | Bayer Ag | Substituierte Xanthine |
| US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| WO2001094350A1 (en) | 2000-06-07 | 2001-12-13 | Almirall Prodesfarma S.A. | 6-phenylpyrrolopyrimidinedione derivatives |
| ES2193839B1 (es) * | 2001-06-22 | 2005-02-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de 6-fenildihidropirrolpirimidindiona. |
| WO2003006465A1 (en) * | 2001-07-13 | 2003-01-23 | Cv Therapeutics, Inc. | Partial and full agonist of a adenosine receptors |
| US7157440B2 (en) * | 2001-07-13 | 2007-01-02 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
| ATE520694T1 (de) * | 2001-11-09 | 2011-09-15 | Gilead Palo Alto Inc | A2b-adenosinrezeptorantagonisten |
-
2004
- 2004-10-26 US US10/973,167 patent/US7449473B2/en not_active Expired - Lifetime
- 2004-10-26 JP JP2006538172A patent/JP4863876B2/ja not_active Expired - Lifetime
- 2004-10-26 BR BRPI0415888-1A patent/BRPI0415888A/pt not_active Application Discontinuation
- 2004-10-26 MX MXPA06004789A patent/MXPA06004789A/es unknown
- 2004-10-26 AU AU2004285013A patent/AU2004285013A1/en not_active Abandoned
- 2004-10-26 CN CNA200480031969XA patent/CN1890241A/zh active Pending
- 2004-10-26 DE DE602004018808T patent/DE602004018808D1/de not_active Expired - Lifetime
- 2004-10-26 KR KR1020067008426A patent/KR20060111467A/ko not_active Withdrawn
- 2004-10-26 CA CA2544193A patent/CA2544193C/en not_active Expired - Lifetime
- 2004-10-26 ES ES04810023T patent/ES2318363T3/es not_active Expired - Lifetime
- 2004-10-26 AT AT04810023T patent/ATE419252T1/de not_active IP Right Cessation
- 2004-10-26 EP EP04810023A patent/EP1678181B1/en not_active Expired - Lifetime
- 2004-10-26 WO PCT/US2004/035453 patent/WO2005042534A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007509947A5 (https=) | ||
| CA2544193A1 (en) | A2b adenosine receptor antagonists | |
| CN113195441B (zh) | 雄激素受体调节剂及其使用方法 | |
| JP2005509036A5 (https=) | ||
| JP5461398B2 (ja) | 含窒素芳香族ヘテロシクリル化合物 | |
| EP3555078B1 (en) | Bisaryl heterocycles as nrf2 activators | |
| JP2015523353A (ja) | ｍＰＧＥＳ−１阻害剤としてのトリアゾロン化合物 | |
| US20080021011A1 (en) | Therapeutic compounds | |
| JP2004107299A (ja) | 新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤 | |
| US12091409B2 (en) | Ether linked triazoles as NRF2 activators | |
| WO2003064410A1 (en) | Novel 1,2,4-triazole compound | |
| JP2008543860A5 (https=) | ||
| JP2006518390A (ja) | Ａ１アデノシンレセプターアンタゴニスト | |
| JP2024032976A (ja) | アデノシン受容体アンタゴニストおよびその使用 | |
| MXPA04007736A (es) | Derivados de nicotinamida utiles como inhibidores de pde4. | |
| CN113563319A (zh) | 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物 | |
| WO2014078309A1 (en) | Cannabinoid receptor mediating compounds | |
| JP2008509955A5 (https=) | ||
| JP2011157349A (ja) | 含窒素芳香族ヘテロシクリル化合物を含有する医薬組成物 | |
| WO2001042244A1 (en) | Novel 1,8-naphthyridin-2(1h)-one derivatives | |
| EP3555068B1 (en) | 3-oxo-1,4-diazepinyle compounds as nrf2 activators | |
| JP2008088107A (ja) | 新規ピリダジン誘導体 | |
| CN111662239B (zh) | 1,2,4-三唑类化合物及其制法和药物用途 | |
| JP2007524705A5 (https=) | ||
| CA2533663A1 (en) | Nicotinamide derivatives useful as pde4 inhibitors |